Identification

Name
Zidovudine
Accession Number
DB00495  (APRD00449)
Type
Small Molecule
Groups
Approved
Description

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]

Structure
Thumb
Synonyms
  • Azidothymidine
  • AZT
  • ZDV
  • Zidovudin
  • Zidovudinum
External IDs
BW-A-509U / BW-A509U / NSC-602670
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RetrovirSyrup10 mg/mLOralViiV Healthcare ULC2010-10-28Not applicableUs
RetrovirCapsule100 mg/1OralViiV Healthcare ULC2010-10-28Not applicableUs
RetrovirInjection, solution10 mg/mLIntravenousViiV Healthcare ULC2010-11-04Not applicableUs
Retrovir (azt)Capsule100 mgOralViiV Healthcare ULC1990-12-31Not applicableCanada
Retrovir (azt)Syrup50 mgOralViiV Healthcare ULC1991-12-31Not applicableCanada
Retrovir (azt)Liquid10 mgIntravenousViiV Healthcare ULC1991-12-31Not applicableCanada
Retrovir (azt) 300mgTablet300 mgOralGlaxo Wellcome1998-09-232000-11-30Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-zidovudineCapsule100 mgOralApotex Corporation1992-12-31Not applicableCanada
Lamivudine and ZidovudineTablet, film coated150 mg/1OralRemedy Repack2013-04-112016-10-13Us
Novo-azt Cap 100mgCapsule100 mgOralNovopharm Limited1992-12-312015-10-26Canada
ZidovudineCapsule100 mg/1OralAmerincan Health Packaging2011-02-012018-10-31Us
ZidovudineTablet300 mg/1OralRoxane Laboratories2005-09-192016-10-13Us
ZidovudineTablet, film coated300 mg/1OralRemedy Repack2012-01-172016-10-26Us
ZidovudineTablet, film coated300 mg/1OralLucid Pharma Llc2005-09-19Not applicableUs
ZidovudineTablet300 mg/1OralAvera Mc Kennan Hospital2016-01-272018-07-12Us
ZidovudineCapsule100 mg/1OralAcetris Health, Llc2006-03-27Not applicableUs
ZidovudineTablet, film coated300 mg/1OralRemedy Repack2015-05-192017-04-14Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Abacavir Sulfate, Lamivudine and ZidovudineZidovudine (300 mg/1) + Abacavir Sulfate (300 mg/1) + Lamivudine (150 mg/1)TabletOralLupin Pharmaceuticals2013-12-17Not applicableUs
Abacavir, Lamivudine and ZidovudineZidovudine (300 mg/1) + Abacavir Sulfate (300 mg/1) + Lamivudine (150 mg/1)TabletOralLupin Pharmaceuticals2013-12-17Not applicableUs
Apo-abacavir-lamivudine-zidovudineZidovudine (300 mg) + Abacavir (300 mg) + Lamivudine (150 mg)TabletOralApotex Corporation2015-12-28Not applicableCanada
Apo-lamivudine-zidovudineZidovudine (300 mg) + Lamivudine (150 mg)TabletOralApotex Corporation2012-06-04Not applicableCanada
Apo-zidovudine-lamivudine-nevirapineZidovudine (300 mg) + Lamivudine (150 mg) + Nevirapine (200 mg)TabletOralApotex CorporationNot applicableNot applicableCanada
Auro-lamivudine/zidovudineZidovudine (300 mg) + Lamivudine (150 mg)TabletOralAuro Pharma Inc2014-03-03Not applicableCanada
CombivirZidovudine (300 mg/1) + Lamivudine (150 mg/1)Tablet, film coatedOralRemedy Repack2013-04-232017-11-22Us49702 0202 18 nlmimage10 34191a68
CombivirZidovudine (300 mg) + Lamivudine (150 mg)TabletOralViiV Healthcare ULC1998-12-08Not applicableCanada
CombivirZidovudine (300 mg/1) + Lamivudine (150 mg/1)Tablet, film coatedOralA S Medication Solutions2010-10-192017-06-20Us
CombivirZidovudine (300 mg/1) + Lamivudine (150 mg/1)Tablet, film coatedOralViiV Healthcare ULC2010-10-19Not applicableUs
Categories
UNII
4B9XT59T7S
CAS number
30516-87-1
Weight
Average: 267.2413
Monoisotopic: 267.096753929
Chemical Formula
C10H13N5O4
InChI Key
HBOMLICNUCNMMY-XLPZGREQSA-N
InChI
InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1
IUPAC Name
1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O

Pharmacology

Indication

Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.

Associated Conditions
Pharmacodynamics

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Zidovudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.

Mechanism of action

Zidovudine, a structural analog of thymidine, is a prodrug that must be phosphorylated to its active 5′-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). It inhibits the activity of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. It competes with the natural substrate dGTP and incorporates itself into viral DNA. It is also a weak inhibitor of cellular DNA polymerase α and γ.

TargetActionsOrganism
AReverse transcriptase/RNaseH
inhibitor
Human immunodeficiency virus 1
UTelomerase reverse transcriptase
inhibitor
Human
Absorption

Rapid and nearly complete absorption from the gastrointestinal tract following oral administration; however, because of first-pass metabolism, systemic bioavailability of zidovudine capsules and solution is approximately 65% (range, 52 to 75%). Bioavailability in neonates up to 14 days of age is approximately 89%, and it decreases to approximately 61% and 65% in neonates over 14 days of age and children 3 months to 12 years, respectively. Administration with a high-fat meal may decrease the rate and extent of absorption.

Volume of distribution

Apparent volume of distribution, HIV-infected patients, IV administration = 1.6 ± 0.6 L/kg

Protein binding

30-38%

Metabolism

Hepatic. Metabolized by glucuronide conjugation to major, inactive metabolite, 3′-azido-3′-deoxy-5′- O-beta-D-glucopyranuronosylthymidine (GZDV). UGT2B7 is the primary UGT isoform that is responsible for glucuronidation. Compared to zidovudine, GZDV's area under the curve is approximately 3-fold greater. The cytochrome P450 isozymes are responsible for the reduction of the azido moiety to form 3'-amino-3'- deoxythymidine (AMT).

Route of elimination

As in adult patients, the major route of elimination was by metabolism to GZDV. After intravenous dosing, about 29% of the dose was excreted in the urine unchanged and about 45% of the dose was excreted as GZDV.

Half life

Elimination half life, HIV-infected patients, IV administration = 1.1 hours (range of 0.5 - 2.9 hours)

Clearance
  • 0.65 +/- 0.29 L/hr/kg [HIV-infected, Birth to 14 Days of Age]
  • 1.14 +/- 0.24 L/hr/kg [HIV-infected, 14 Days to 3 Months of Age]
  • 1.85 +/- 0.47 L/hr/kg [HIV-infected, 3 Months to 12 Years of Age]. The transporters, ABCB1, ABCC4, ABCC5, and ABCG2 are involved with the clearance of zidovudine.
Toxicity

Symptoms of overdose include fatigue, headache, nausea, and vomiting. LD50 is 3084 mg/kg (orally in mice).

Affected organisms
  • Human Immunodeficiency Virus
Pathways
PathwayCategory
Zidovudine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Zidovudine.Experimental
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Zidovudine.Investigational
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Zidovudine.Approved, Investigational
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Zidovudine.Approved
AbemaciclibThe serum concentration of Zidovudine can be increased when it is combined with Abemaciclib.Approved, Investigational
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Zidovudine.Investigational
AbirateroneThe metabolism of Zidovudine can be decreased when combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Zidovudine.Approved
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Zidovudine.Investigational
AcyclovirAcyclovir may increase the central nervous system depressant (CNS depressant) activities of Zidovudine.Approved
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Zidovudine.Approved
AfatinibThe serum concentration of Zidovudine can be increased when it is combined with Afatinib.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Zidovudine.Investigational
AlbendazoleThe serum concentration of Zidovudine can be increased when it is combined with Albendazole.Approved, Vet Approved
Albinterferon Alfa-2BThe risk or severity of adverse effects can be increased when Albinterferon Alfa-2B is combined with Zidovudine.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Alclometasone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Zidovudine.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Zidovudine can be increased when it is combined with Alectinib.Approved, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Zidovudine.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Zidovudine.Approved, Investigational
AllopurinolThe excretion of Allopurinol can be decreased when combined with Zidovudine.Approved
AlprostadilThe excretion of Alprostadil can be decreased when combined with Zidovudine.Approved, Investigational
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Zidovudine.Approved
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Aluminium clofibrate.Experimental
AlvocidibThe serum concentration of Alvocidib can be decreased when it is combined with Zidovudine.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Amcinonide.Approved
Aminohippuric acidThe excretion of Zidovudine can be decreased when combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Zidovudine can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Zidovudine.Approved
AmlodipineThe serum concentration of Zidovudine can be increased when it is combined with Amlodipine.Approved
AmodiaquineZidovudine may increase the neutropenic activities of Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Zidovudine can be increased when it is combined with Amoxapine.Approved
AmprenavirThe metabolism of Zidovudine can be decreased when combined with Amprenavir.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Zidovudine.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Zidovudine.Approved
AnnamycinThe serum concentration of Zidovudine can be increased when it is combined with Annamycin.Investigational
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Zidovudine.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Zidovudine.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Zidovudine.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Zidovudine.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zidovudine.Approved
ApalutamideThe serum concentration of Zidovudine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Zidovudine.Approved, Investigational
AprepitantThe serum concentration of Zidovudine can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe metabolism of Zidovudine can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Arsenic trioxide.Approved, Investigational
AspartameThe excretion of Zidovudine can be decreased when combined with Aspartame.Approved, Nutraceutical
AstemizoleThe serum concentration of Zidovudine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtalurenThe excretion of Zidovudine can be decreased when combined with Ataluren.Approved, Investigational
AtazanavirThe metabolism of Zidovudine can be decreased when combined with Atazanavir.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Zidovudine.Approved
AvatrombopagThe serum concentration of Zidovudine can be increased when it is combined with Avatrombopag.Approved, Investigational
AvibactamThe excretion of Avibactam can be decreased when combined with Zidovudine.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Zidovudine.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Zidovudine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Zidovudine.Approved
AzelastineThe serum concentration of Zidovudine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Zidovudine can be increased when it is combined with Azithromycin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Zidovudine.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Zidovudine.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Zidovudine.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Zidovudine.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Zidovudine.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Zidovudine.Approved
BaclofenThe excretion of Zidovudine can be decreased when combined with Baclofen.Approved
Bafilomycin A1The serum concentration of Zidovudine can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Zidovudine can be increased when it is combined with Bafilomycin B1.Experimental
BaricitinibThe serum concentration of Zidovudine can be increased when it is combined with Baricitinib.Approved, Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Zidovudine.Approved, Investigational
BCG vaccineThe risk or severity of infection can be increased when BCG vaccine is combined with Zidovudine.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Zidovudine.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Beclomethasone dipropionate.Approved, Investigational
BegelomabThe risk or severity of adverse effects can be increased when Begelomab is combined with Zidovudine.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Zidovudine.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Zidovudine.Approved
BelinostatThe risk or severity of adverse effects can be increased when Zidovudine is combined with Belinostat.Approved, Investigational
BendamustineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Bendamustine.Approved, Investigational
Benzoic AcidThe excretion of Zidovudine can be decreased when combined with Benzoic Acid.Approved, Investigational
BenzquinamideThe serum concentration of Zidovudine can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe serum concentration of Zidovudine can be increased when it is combined with Benzyl alcohol.Approved
BenzylpenicillinThe excretion of Zidovudine can be decreased when combined with Benzylpenicillin.Approved, Vet Approved
BepridilThe serum concentration of Zidovudine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Zidovudine.Approved, Vet Approved
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Zidovudine.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Bexarotene is combined with Zidovudine.Approved, Investigational
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Bezafibrate.Approved, Investigational
BicalutamideThe serum concentration of Zidovudine can be increased when it is combined with Bicalutamide.Approved
BictegravirThe serum concentration of Bictegravir can be decreased when it is combined with Zidovudine.Approved, Investigational
BinimetinibThe serum concentration of Binimetinib can be decreased when it is combined with Zidovudine.Approved, Investigational
Biricodar dicitrateThe serum concentration of Zidovudine can be increased when it is combined with Biricodar dicitrate.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Zidovudine.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Zidovudine.Approved, Investigational
BoceprevirThe metabolism of Zidovudine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Zidovudine.Approved, Investigational
BosentanThe serum concentration of Zidovudine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe risk or severity of adverse effects can be increased when Zidovudine is combined with Bosutinib.Approved
Brefeldin AThe serum concentration of Zidovudine can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Zidovudine.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Zidovudine is combined with Briakinumab.Investigational
BrigatinibThe serum concentration of Zidovudine can be increased when it is combined with Brigatinib.Approved, Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Zidovudine.Approved, Investigational
BromocriptineThe serum concentration of Zidovudine can be increased when it is combined with Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Zidovudine.Approved
BumetanideThe excretion of Zidovudine can be decreased when combined with Bumetanide.Approved
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Zidovudine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Zidovudine can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Zidovudine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Zidovudine.Approved
CaffeineThe serum concentration of Zidovudine can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Zidovudine can be increased when it is combined with Canagliflozin.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Zidovudine.Approved, Investigational
CannabidiolThe serum concentration of Zidovudine can be increased when it is combined with Cannabidiol.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Zidovudine.Approved, Investigational
Caprylic acidThe excretion of Zidovudine can be decreased when combined with Caprylic acid.Approved, Experimental, Investigational
CaptoprilThe serum concentration of Zidovudine can be increased when it is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Carbamazepine.Approved, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Zidovudine.Approved
CarfilzomibThe risk or severity of adverse effects can be increased when Zidovudine is combined with Carfilzomib.Approved, Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Zidovudine.Approved, Investigational
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Zidovudine.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Zidovudine.Experimental
CefacetrileThe excretion of Zidovudine can be decreased when combined with Cefacetrile.Approved
CefaclorThe excretion of Cefaclor can be decreased when combined with Zidovudine.Approved
CefadroxilThe excretion of Zidovudine can be decreased when combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe excretion of Zidovudine can be decreased when combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe excretion of Zidovudine can be decreased when combined with Cefamandole.Approved, Investigational
CefazolinThe excretion of Zidovudine can be decreased when combined with Cefazolin.Approved
CefdinirThe excretion of Cefdinir can be decreased when combined with Zidovudine.Approved
CefoperazoneThe serum concentration of Zidovudine can be increased when it is combined with Cefoperazone.Approved, Investigational
CefotaximeThe excretion of Zidovudine can be decreased when combined with Cefotaxime.Approved
CefotiamThe excretion of Cefotiam can be decreased when combined with Zidovudine.Approved, Investigational
CeftibutenThe excretion of Ceftibuten can be decreased when combined with Zidovudine.Approved, Investigational
CeftizoximeThe excretion of Ceftizoxime can be decreased when combined with Zidovudine.Approved, Investigational
CeftriaxoneThe serum concentration of Zidovudine can be increased when it is combined with Ceftriaxone.Approved
Cepeginterferon alfa-2BThe risk or severity of adverse effects can be increased when Cepeginterferon alfa-2B is combined with Zidovudine.Investigational
CephalexinThe excretion of Zidovudine can be decreased when combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloridineThe excretion of Cephaloridine can be decreased when combined with Zidovudine.Approved, Withdrawn
CeritinibThe serum concentration of Zidovudine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Zidovudine.Approved, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Zidovudine.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Zidovudine.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Chloramphenicol is combined with Zidovudine.Approved, Vet Approved
ChloroformThe serum concentration of Zidovudine can be increased when it is combined with Chloroform.Vet Approved
ChlorpromazineThe serum concentration of Zidovudine can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe serum concentration of Zidovudine can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
Cholic AcidThe excretion of Zidovudine can be decreased when combined with Cholic Acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Ciclesonide.Approved, Investigational
CilastatinThe excretion of Zidovudine can be decreased when combined with Cilastatin.Approved, Investigational
CimetidineThe excretion of Zidovudine can be decreased when combined with Cimetidine.Approved, Investigational
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Ciprofibrate.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Zidovudine.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Zidovudine.Approved, Investigational
ClarithromycinClarithromycin may increase the myelosuppressive activities of Zidovudine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Zidovudine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Clocortolone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Zidovudine.Approved, Investigational
ClofazimineThe serum concentration of Zidovudine can be increased when it is combined with Clofazimine.Approved, Investigational
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Clofibride.Experimental
ClomipramineThe metabolism of Zidovudine can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
CloprednolThe risk or severity of adverse effects can be increased when Zidovudine is combined with Cloprednol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Zidovudine.Approved
ClotrimazoleThe metabolism of Zidovudine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Clozapine.Approved
CobicistatThe metabolism of Zidovudine can be decreased when combined with Cobicistat.Approved
CodeineThe serum concentration of Codeine can be decreased when it is combined with Zidovudine.Approved, Illicit
ColchicineThe serum concentration of Zidovudine can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Zidovudine can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Zidovudine.Approved, Investigational
Conjugated estrogensThe excretion of Zidovudine can be decreased when combined with Conjugated estrogens.Approved
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Zidovudine.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Zidovudine.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Zidovudine is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Zidovudine.Approved
CrizotinibThe serum concentration of Zidovudine can be increased when it is combined with Crizotinib.Approved
CurcuminThe metabolism of Zidovudine can be decreased when combined with Curcumin.Approved, Investigational
Cyclic Adenosine MonophosphateThe excretion of Cyclic Adenosine Monophosphate can be decreased when combined with Zidovudine.Experimental
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Zidovudine.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Zidovudine.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Zidovudine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Zidovudine.Approved, Investigational
DabrafenibThe serum concentration of Zidovudine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Zidovudine.Approved, Investigational
DaclatasvirThe serum concentration of Zidovudine can be increased when it is combined with Daclatasvir.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Zidovudine.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Zidovudine.Approved, Investigational
DaidzinThe serum concentration of Zidovudine can be increased when it is combined with Daidzin.Experimental
DanazolThe metabolism of Zidovudine can be decreased when combined with Danazol.Approved
DarunavirThe metabolism of Zidovudine can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Zidovudine can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Zidovudine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Zidovudine.Approved
DecitabineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Zidovudine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Zidovudine.Approved, Investigational
DelafloxacinThe serum concentration of Delafloxacin can be decreased when it is combined with Zidovudine.Approved, Investigational
DelavirdineThe metabolism of Zidovudine can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Zidovudine is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Zidovudine.Investigational
DesipramineThe serum concentration of Zidovudine can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Zidovudine can be increased when it is combined with Desmethylsertraline.Experimental
DesonideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Desoximetasone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Zidovudine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Zidovudine.Approved, Investigational
DexniguldipineThe serum concentration of Zidovudine can be increased when it is combined with Dexniguldipine.Experimental
DexrazoxaneThe risk or severity of adverse effects can be increased when Dexrazoxane is combined with Zidovudine.Approved, Withdrawn
DexverapamilThe serum concentration of Zidovudine can be increased when it is combined with Dexverapamil.Experimental
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Zidovudine.Approved, Vet Approved
Diethyl etherThe serum concentration of Zidovudine can be increased when it is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Zidovudine can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DiflorasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Diflorasone.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Difluprednate.Approved
DigoxinThe excretion of Zidovudine can be decreased when combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Zidovudine can be increased when it is combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Zidovudine can be decreased when combined with Diltiazem.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Zidovudine.Approved, Investigational
DinoprostoneThe excretion of Zidovudine can be decreased when combined with Dinoprostone.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Zidovudine.Approved, Investigational
DipyridamoleThe serum concentration of Zidovudine can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Zidovudine.Approved, Investigational
DofequidarThe serum concentration of Zidovudine can be increased when it is combined with Dofequidar.Experimental, Investigational
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Zidovudine.Approved
DovitinibThe serum concentration of Zidovudine can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe serum concentration of Zidovudine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Zidovudine can be increased when it is combined with Doxepin.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Zidovudine.Investigational
DoxycyclineThe metabolism of Zidovudine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Zidovudine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Zidovudine can be increased when it is combined with Dronedarone.Approved
DuloxetineThe serum concentration of Zidovudine can be increased when it is combined with Duloxetine.Approved
EconazoleThe serum concentration of Zidovudine can be increased when it is combined with Econazole.Approved
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Zidovudine.Approved, Investigational
EdaravoneThe excretion of Edaravone can be decreased when combined with Zidovudine.Approved, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with Zidovudine.Approved, Investigational
EfavirenzThe serum concentration of Zidovudine can be decreased when it is combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Zidovudine can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be decreased when it is combined with Zidovudine.Approved, Investigational
Ellagic AcidThe excretion of Ellagic Acid can be decreased when combined with Zidovudine.Investigational
EltrombopagThe serum concentration of Zidovudine can be increased when it is combined with Eltrombopag.Approved
EluxadolineThe excretion of Eluxadoline can be decreased when combined with Zidovudine.Approved, Investigational
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Zidovudine.Approved
EmopamilThe serum concentration of Zidovudine can be increased when it is combined with Emopamil.Experimental
EnalaprilThe excretion of Zidovudine can be decreased when combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Enasidenib can be decreased when it is combined with Zidovudine.Approved, Investigational
EnzalutamideThe serum concentration of Zidovudine can be decreased when it is combined with Enzalutamide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Zidovudine.Approved
ErgonovineThe serum concentration of Zidovudine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Zidovudine can be increased when it is combined with Ergotamine.Approved
EribulinThe risk or severity of adverse effects can be increased when Zidovudine is combined with Eribulin.Approved, Investigational
ErlotinibThe serum concentration of Zidovudine can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Zidovudine can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
Eslicarbazepine acetateThe metabolism of Zidovudine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Zidovudine can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Zidovudine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be decreased when it is combined with Zidovudine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be decreased when it is combined with Zidovudine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Zidovudine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be decreased when it is combined with Zidovudine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Zidovudine.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Zidovudine.Approved, Investigational
EstroneThe serum concentration of Zidovudine can be increased when it is combined with Estrone.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Zidovudine.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Zidovudine.Approved
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Etofibrate.Approved
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Zidovudine.Approved
EtravirineThe serum concentration of Zidovudine can be decreased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Zidovudine.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Zidovudine.Approved
EzogabineThe serum concentration of Ezogabine can be decreased when it is combined with Zidovudine.Approved, Investigational
FamotidineThe excretion of Zidovudine can be decreased when combined with Famotidine.Approved
FelodipineThe serum concentration of Zidovudine can be increased when it is combined with Felodipine.Approved, Investigational
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Zidovudine.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Fenofibric acid.Approved
FentanylThe serum concentration of Zidovudine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe excretion of Fexofenadine can be decreased when combined with Zidovudine.Approved, Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Zidovudine.Approved, Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Zidovudine.Approved
FlucloroloneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluclorolone.Experimental
FlucytosineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Zidovudine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Zidovudine.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluocortolone.Approved, Withdrawn
FluoresceinThe excretion of Fluorescein can be decreased when combined with Zidovudine.Approved
FluorometholoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Zidovudine.Approved
FluoxetineThe metabolism of Zidovudine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Zidovudine can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluperolone.Experimental
FluphenazineThe serum concentration of Zidovudine can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Zidovudine can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe serum concentration of Flurbiprofen can be decreased when it is combined with Zidovudine.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Zidovudine.Approved
FluvoxamineThe metabolism of Zidovudine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormocortalThe risk or severity of adverse effects can be increased when Zidovudine is combined with Formocortal.Experimental
FosamprenavirThe metabolism of Zidovudine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Zidovudine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Zidovudine can be increased when combined with Fosphenytoin.Approved, Investigational
FostamatinibThe serum concentration of Zidovudine can be increased when it is combined with Fostamatinib.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Zidovudine.Approved, Investigational
FurosemideThe serum concentration of Furosemide can be decreased when it is combined with Zidovudine.Approved, Vet Approved
Fusidic AcidThe serum concentration of Zidovudine can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Zidovudine.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with Zidovudine.Approved, Investigational
GallopamilThe serum concentration of Zidovudine can be increased when it is combined with Gallopamil.Investigational
GanciclovirThe risk or severity of adverse effects can be increased when Ganciclovir is combined with Zidovudine.Approved, Investigational
GavestinelThe serum concentration of Gavestinel can be decreased when it is combined with Zidovudine.Investigational
GefitinibThe serum concentration of Zidovudine can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Zidovudine.Approved
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Zidovudine.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Zidovudine.Approved, Investigational
GenisteinThe serum concentration of Zidovudine can be increased when it is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Zidovudine.Investigational
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer is combined with Zidovudine.Approved, Investigational
GlecaprevirThe serum concentration of Zidovudine can be increased when it is combined with Glecaprevir.Approved, Investigational
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Zidovudine.Approved, Investigational
Glutaric AcidThe excretion of Zidovudine can be decreased when combined with Glutaric Acid.Experimental
GlyburideThe serum concentration of Zidovudine can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Zidovudine can be increased when it is combined with Glycerin.Approved, Investigational
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Zidovudine.Approved
Gramicidin DThe serum concentration of Zidovudine can be increased when it is combined with Gramicidin D.Approved
GuanidineThe excretion of Zidovudine can be decreased when combined with Guanidine.Approved
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Zidovudine.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Zidovudine is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Halometasone.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Zidovudine.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Zidovudine.Approved, Withdrawn
HesperetinThe serum concentration of Zidovudine can be increased when it is combined with Hesperetin.Approved
HM-30181The serum concentration of Zidovudine can be increased when it is combined with HM-30181.Experimental
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Zidovudine.Approved
HycanthoneThe serum concentration of Zidovudine can be increased when it is combined with Hycanthone.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Zidovudine.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroxychloroquineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Hydroxychloroquine.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Zidovudine.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Zidovudine.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Zidovudine.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Zidovudine.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Zidovudine.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Zidovudine.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Zidovudine.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Zidovudine.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Zidovudine.Approved
ImipramineThe metabolism of Zidovudine can be decreased when combined with Imipramine.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Zidovudine.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Zidovudine.Approved
IndinavirThe metabolism of Zidovudine can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Zidovudine.Approved, Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Zidovudine.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Zidovudine.Investigational
Interferon Alfa-2a, RecombinantThe risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Zidovudine.Approved, Investigational
Interferon Alfa-2b, RecombinantThe risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Zidovudine.Approved
Interferon alfa-n1The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Zidovudine.Approved, Investigational
Interferon beta-1aThe risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Zidovudine.Approved, Investigational
Interferon beta-1bThe risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Zidovudine.Approved
Interferon gamma-1bThe risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Zidovudine.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Zidovudine.Approved, Investigational
IsavuconazoleThe serum concentration of Zidovudine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Zidovudine can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Zidovudine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineThe serum concentration of Zidovudine can be increased when it is combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Zidovudine can be decreased when combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Zidovudine can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Zidovudine can be increased when it is combined with Ivosidenib.Approved, Investigational
IxabepiloneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Ixabepilone.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Zidovudine.Approved
KetoconazoleThe metabolism of Zidovudine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe serum concentration of Ketoprofen can be decreased when it is combined with Zidovudine.Approved, Vet Approved
L-CarnitineThe excretion of L-Carnitine can be decreased when combined with Zidovudine.Approved, Investigational
L-CitrullineThe excretion of L-Citrulline can be decreased when combined with Zidovudine.Approved, Investigational, Nutraceutical
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Zidovudine.Approved, Investigational, Nutraceutical
LamotrigineThe serum concentration of Zidovudine can be decreased when it is combined with Lamotrigine.Approved, Investigational
LaniquidarThe serum concentration of Zidovudine can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Zidovudine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Zidovudine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Zidovudine can be increased when it is combined with Ledipasvir.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Zidovudine.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Zidovudine.Approved
LenvatinibThe excretion of Zidovudine can be decreased when combined with Lenvatinib.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be decreased when it is combined with Zidovudine.Approved, Investigational
LeucovorinThe excretion of Leucovorin can be decreased when combined with Zidovudine.Approved
LevofloxacinThe serum concentration of Zidovudine can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Zidovudine.Approved
LidocaineThe serum concentration of Zidovudine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Zidovudine can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Zidovudine is combined with Linezolid.Approved, Investigational
LiothyronineThe excretion of Zidovudine can be decreased when combined with Liothyronine.Approved, Vet Approved
LiotrixThe excretion of Zidovudine can be decreased when combined with Liotrix.Approved
LipegfilgrastimZidovudine may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LomerizineThe serum concentration of Zidovudine can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Zidovudine can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Zidovudine.Approved, Investigational
LonafarnibThe serum concentration of Zidovudine can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe serum concentration of Zidovudine can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Zidovudine can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Zidovudine can be increased when it is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Zidovudine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Zidovudine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Zidovudine is combined with Loteprednol.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Zidovudine.Approved, Investigational
LoxapineThe serum concentration of Zidovudine can be increased when it is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Zidovudine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Zidovudine can be decreased when it is combined with Lumacaftor.Approved
LusutrombopagThe serum concentration of Zidovudine can be increased when it is combined with Lusutrombopag.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Zidovudine.Approved, Investigational
Medical CannabisThe serum concentration of Zidovudine can be increased when it is combined with Medical Cannabis.Experimental, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Medrysone.Approved
MefloquineThe serum concentration of Zidovudine can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Zidovudine can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelatoninThe excretion of Zidovudine can be decreased when combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Zidovudine is combined with Melengestrol.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Zidovudine.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Zidovudine.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Meprednisone.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Zidovudine.Approved
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Zidovudine.Approved, Investigational, Withdrawn
MethimazoleThe risk or severity of adverse effects can be increased when Zidovudine is combined with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Zidovudine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Zidovudine.Approved, Vet Approved
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Zidovudine.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Zidovudine is combined with Mevastatin.Experimental
MibefradilThe metabolism of Zidovudine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Zidovudine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Zidovudine can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Zidovudine can be increased when it is combined with Mifepristone.Approved, Investigational
MinocyclineThe excretion of Zidovudine can be decreased when combined with Minocycline.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Zidovudine.Approved
MitotaneThe serum concentration of Zidovudine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Zidovudine.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Zidovudine.Investigational
MoclobemideThe metabolism of Zidovudine can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe serum concentration of Zidovudine can be decreased when it is combined with Modafinil.Approved, Investigational
MometasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Mometasone furoate.Approved, Vet Approved
MonensinThe serum concentration of Zidovudine can be increased when it is combined with Monensin.Vet Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Zidovudine.Approved, Investigational
MuraglitazarThe serum concentration of Muraglitazar can be decreased when it is combined with Zidovudine.Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Zidovudine.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zidovudine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zidovudine.Approved
NabiximolsThe serum concentration of Zidovudine can be increased when it is combined with Nabiximols.Approved, Investigational
NafcillinThe serum concentration of Zidovudine can be decreased when it is combined with Nafcillin.Approved, Investigational
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Zidovudine.Approved, Vet Approved
NaltrexoneThe serum concentration of Naltrexone can be decreased when it is combined with Zidovudine.Approved, Investigational, Vet Approved
NaproxenThe serum concentration of Naproxen can be decreased when it is combined with Zidovudine.Approved, Vet Approved
NaringeninThe serum concentration of Zidovudine can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Zidovudine.Approved, Investigational
Natural alpha interferonThe risk or severity of adverse effects can be increased when Natural alpha interferon is combined with Zidovudine.Approved, Investigational
NefazodoneThe metabolism of Zidovudine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Zidovudine.Approved, Investigational
NelfinavirThe serum concentration of Zidovudine can be decreased when it is combined with Nelfinavir.Approved
NeratinibThe serum concentration of Zidovudine can be increased when it is combined with Neratinib.Approved, Investigational
NetupitantThe serum concentration of Zidovudine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Zidovudine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Zidovudine can be increased when it is combined with Nicardipine.Approved, Investigational
NigericinThe serum concentration of Zidovudine can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Zidovudine can be increased when it is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Zidovudine.Approved, Investigational
NimodipineThe serum concentration of Zidovudine can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Zidovudine can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Zidovudine can be increased when it is combined with Nitrendipine.Approved, Investigational
NovobiocinThe serum concentration of Zidovudine can be increased when it is combined with Novobiocin.Approved, Investigational, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Zidovudine.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Zidovudine is combined with Ocrelizumab.Approved, Investigational
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Zidovudine.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Zidovudine is combined with Olaparib.Approved
OmeprazoleThe serum concentration of Zidovudine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
ONT-093The serum concentration of Zidovudine can be increased when it is combined with ONT-093.Investigational
OseltamivirThe excretion of Oseltamivir can be decreased when combined with Zidovudine.Approved
OsimertinibThe serum concentration of Zidovudine can be increased when it is combined with Osimertinib.Approved
OuabainThe excretion of Zidovudine can be decreased when combined with Ouabain.Approved
Oxalic AcidThe excretion of Oxalic Acid can be decreased when combined with Zidovudine.Experimental
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Zidovudine.Approved, Investigational
OxcarbazepineThe serum concentration of Zidovudine can be decreased when it is combined with Oxcarbazepine.Approved
OxytetracyclineThe excretion of Zidovudine can be decreased when combined with Oxytetracycline.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Zidovudine.Approved, Vet Approved
PalbociclibThe serum concentration of Zidovudine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliferminThe therapeutic efficacy of Palifermin can be decreased when used in combination with Zidovudine.Approved
PaliperidoneThe serum concentration of Zidovudine can be increased when it is combined with Paliperidone.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Zidovudine.Approved, Investigational
PantoprazoleThe serum concentration of Zidovudine can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Paramethasone.Approved
ParitaprevirThe serum concentration of Zidovudine can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe serum concentration of Zidovudine can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Zidovudine.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Zidovudine.Approved, Investigational
Peginterferon beta-1aThe risk or severity of adverse effects can be increased when Peginterferon beta-1a is combined with Zidovudine.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Zidovudine.Approved, Investigational
PentazocineThe serum concentration of Zidovudine can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Zidovudine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Zidovudine.Approved, Investigational
PethidineThe serum concentration of Zidovudine can be increased when it is combined with Pethidine.Approved
PhenobarbitalThe serum concentration of Zidovudine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenylbutazoneThe excretion of Zidovudine can be decreased when combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Zidovudine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Zidovudine can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Zidovudine.Approved, Investigational
PimozideThe serum concentration of Zidovudine can be increased when it is combined with Pimozide.Approved
PiperacillinThe excretion of Piperacillin can be decreased when combined with Zidovudine.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Zidovudine.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Zidovudine.Approved, Investigational
PiroxicamThe excretion of Zidovudine can be decreased when combined with Piroxicam.Approved, Investigational
PitavastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Zidovudine is combined with Pitavastatin.Approved
PitolisantThe serum concentration of Zidovudine can be decreased when it is combined with Pitolisant.Approved, Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Zidovudine.Approved
PonatinibThe risk or severity of adverse effects can be increased when Zidovudine is combined with Ponatinib.Approved, Investigational
PosaconazoleThe metabolism of Zidovudine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with Zidovudine.Approved, Investigational
PravastatinThe serum concentration of Zidovudine can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Zidovudine can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Zidovudine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Zidovudine.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Prednylidene.Experimental
PrimaquineThe serum concentration of Zidovudine can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Zidovudine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe metabolism of Zidovudine can be decreased when combined with Probenecid.Approved, Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Zidovudine.Approved, Investigational
ProgesteroneThe serum concentration of Zidovudine can be increased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Zidovudine can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Zidovudine can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Zidovudine.Approved, Investigational, Vet Approved
PropylthiouracilThe risk or severity of adverse effects can be increased when Zidovudine is combined with Propylthiouracil.Approved, Investigational
ProtriptylineThe serum concentration of Zidovudine can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Zidovudine can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Zidovudine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe excretion of Quinapril can be decreased when combined with Zidovudine.Approved, Investigational
QuinidineThe serum concentration of Zidovudine can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe metabolism of Zidovudine can be increased when combined with Quinine.Approved
RabeprazoleThe serum concentration of Zidovudine can be increased when it is combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Zidovudine.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Zidovudine.Approved, Investigational
RaltegravirRaltegravir may increase the myopathic rhabdomyolysis activities of Zidovudine.Approved
RaltitrexedThe risk or severity of adverse effects can be increased when Raltitrexed is combined with Zidovudine.Approved, Investigational
RanitidineThe serum concentration of Zidovudine can be increased when it is combined with Ranitidine.Approved
ReboxetineThe serum concentration of Zidovudine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Zidovudine can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Zidovudine can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Zidovudine can be increased when it is combined with Reversin 121.Experimental
RibavirinThe risk or severity of adverse effects can be increased when Zidovudine is combined with Ribavirin.Approved
RifampicinThe serum concentration of Zidovudine can be decreased when it is combined with Rifampicin.Approved
RifamycinThe metabolism of Zidovudine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Zidovudine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Zidovudine can be increased when combined with Rifaximin.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Zidovudine.Approved, Investigational
RilpivirineThe serum concentration of Zidovudine can be increased when it is combined with Rilpivirine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Zidovudine.Investigational
RisperidoneThe metabolism of Zidovudine can be decreased when combined with Risperidone.Approved, Investigational
RitonavirThe serum concentration of Zidovudine can be decreased when it is combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Zidovudine.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Zidovudine.Approved
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Ronifibrate.Experimental
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Zidovudine is combined with Rosuvastatin.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Zidovudine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Zidovudine.Approved, Investigational
RucaparibThe serum concentration of Zidovudine can be increased when it is combined with Rucaparib.Approved, Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Zidovudine.Approved
SafinamideThe serum concentration of Zidovudine can be increased when it is combined with Safinamide.Approved, Investigational
Salicylic acidThe excretion of Zidovudine can be decreased when combined with Salicylic acid.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Zidovudine can be increased when it is combined with Salinomycin.Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Zidovudine.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Zidovudine.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Zidovudine.Approved
SaquinavirThe metabolism of Zidovudine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Zidovudine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe excretion of Saxagliptin can be decreased when combined with Zidovudine.Approved
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Zidovudine.Approved
SertralineThe serum concentration of Zidovudine can be increased when it is combined with Sertraline.Approved
Silibinin AThe excretion of Silibinin A can be decreased when combined with Zidovudine.Experimental, Investigational
SiltuximabThe serum concentration of Zidovudine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Zidovudine can be increased when it is combined with Simeprevir.Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Simfibrate.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Zidovudine.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Zidovudine.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Zidovudine.Approved, Investigational
SitagliptinThe excretion of Sitagliptin can be decreased when combined with Zidovudine.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Zidovudine.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Zidovudine.Investigational
St. John's WortThe serum concentration of Zidovudine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StaurosporineThe serum concentration of Zidovudine can be increased when it is combined with Staurosporine.Experimental
StavudineThe therapeutic efficacy of Stavudine can be decreased when used in combination with Zidovudine.Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with Zidovudine.Approved
StiripentolThe serum concentration of Zidovudine can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Zidovudine.Approved, Investigational
Succinic acidThe excretion of Succinic acid can be decreased when combined with Zidovudine.Approved, Nutraceutical
SulfasalazineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Sulfasalazine.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Zidovudine.Approved, Investigational
SuprofenThe serum concentration of Suprofen can be decreased when it is combined with Zidovudine.Approved, Withdrawn
SuvorexantThe serum concentration of Zidovudine can be increased when it is combined with Suvorexant.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Zidovudine.Approved, Investigational
TamoxifenThe serum concentration of Zidovudine can be increased when it is combined with Tamoxifen.Approved
TariquidarThe serum concentration of Zidovudine can be increased when it is combined with Tariquidar.Investigational
Taurocholic AcidThe serum concentration of Zidovudine can be increased when it is combined with Taurocholic Acid.Experimental
TazobactamThe excretion of Tazobactam can be decreased when combined with Zidovudine.Approved
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Zidovudine.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Zidovudine is combined with Tedizolid phosphate.Approved
TelaprevirThe metabolism of Zidovudine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Zidovudine can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Zidovudine can be increased when it is combined with Telmisartan.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Zidovudine.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Zidovudine.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Zidovudine.Approved
Tenofovir disoproxilThe excretion of Tenofovir disoproxil can be decreased when combined with Zidovudine.Approved, Investigational
TenoxicamThe excretion of Zidovudine can be decreased when combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Zidovudine is combined with Tepoxalin.Vet Approved
TerfenadineThe serum concentration of Zidovudine can be increased when it is combined with Terfenadine.Approved, Withdrawn
TeriflunomideThe serum concentration of Zidovudine can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Zidovudine can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Zidovudine can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Zidovudine can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Zidovudine can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Zidovudine can be decreased when it is combined with Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Zidovudine can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe excretion of Zidovudine can be decreased when combined with Tetracycline.Approved, Vet Approved
TetrandrineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Tetrandrine.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Zidovudine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Zidovudine.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Zidovudine.Approved, Investigational
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Zidovudine.Approved, Investigational
TicagrelorThe serum concentration of Zidovudine can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Zidovudine can be decreased when combined with Ticlopidine.Approved
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Zidovudine.Approved
TipifarnibThe serum concentration of Zidovudine can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Zidovudine can be decreased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Zidovudine is combined with Tixocortol.Approved, Withdrawn
TocilizumabThe serum concentration of Zidovudine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Zidovudine.Approved, Investigational
TofacitinibZidovudine may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Zidovudine can be increased when it is combined with Tolvaptan.Approved
TopiroxostatThe serum concentration of Zidovudine can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Zidovudine.Approved, Investigational
ToremifeneThe serum concentration of Zidovudine can be increased when it is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Zidovudine.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Zidovudine.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Zidovudine.Approved, Investigational
trans-2-hydroxycinnamic acidThe excretion of Zidovudine can be decreased when combined with trans-2-hydroxycinnamic acid.Experimental
TrastuzumabThe risk or severity of adverse effects can be increased when Zidovudine is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Zidovudine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Zidovudine.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Zidovudine.Approved, Vet Approved
TrifluoperazineThe serum concentration of Zidovudine can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Zidovudine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Trifluridine.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Zidovudine is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Zidovudine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Zidovudine.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Zidovudine.Investigational
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Zidovudine.Investigational, Withdrawn
TroleandomycinThe metabolism of Zidovudine can be decreased when combined with Troleandomycin.Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Zidovudine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Zidovudine is combined with Ulobetasol.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Zidovudine.Approved, Investigational
ValaciclovirValaciclovir may increase the central nervous system depressant (CNS depressant) activities of Zidovudine.Approved, Investigational
ValganciclovirThe risk or severity of adverse effects can be increased when Valganciclovir is combined with Zidovudine.Approved, Investigational
ValinomycinThe serum concentration of Zidovudine can be increased when it is combined with Valinomycin.Experimental
Valproic AcidThe serum concentration of Zidovudine can be increased when it is combined with Valproic Acid.Approved, Investigational
ValspodarThe serum concentration of Zidovudine can be increased when it is combined with Valspodar.Investigational
VandetanibThe serum concentration of Zidovudine can be increased when it is combined with Vandetanib.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Zidovudine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Zidovudine.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Zidovudine.Approved
VelpatasvirThe serum concentration of Zidovudine can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Zidovudine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Zidovudine can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Zidovudine can be increased when it is combined with Verapamil.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Zidovudine.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Zidovudine.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Zidovudine.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Zidovudine.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Zidovudine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Zidovudine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Zidovudine.Approved, Investigational
VismodegibThe serum concentration of Zidovudine can be increased when it is combined with Vismodegib.Approved, Investigational
VoacamineThe serum concentration of Zidovudine can be increased when it is combined with Voacamine.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Zidovudine.Investigational
VorapaxarThe serum concentration of Zidovudine can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Zidovudine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Zidovudine is combined with Vorinostat.Approved, Investigational
VoxilaprevirThe serum concentration of Zidovudine can be increased when it is combined with Voxilaprevir.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Wortmannin is combined with Zidovudine.Experimental
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Zidovudine.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Zidovudine.Approved, Investigational
YohimbineThe serum concentration of Zidovudine can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZiprasidoneThe metabolism of Zidovudine can be decreased when combined with Ziprasidone.Approved
ZomepiracThe serum concentration of Zidovudine can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Zidovudine.Approved, Investigational
ZosuquidarThe serum concentration of Zidovudine can be increased when it is combined with Zosuquidar.Investigational
ZucapsaicinThe metabolism of Zidovudine can be decreased when combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. De Clercq E: HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol. 1994 Jan 20;47(2):155-69. [PubMed:7508227]
  2. Yarchoan R, Mitsuya H, Broder S: AIDS therapies. Sci Am. 1988 Oct;259(4):110-9. [PubMed:3072667]
  3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173-80. [PubMed:7935654]
  4. Mitsuya H, Yarchoan R, Broder S: Molecular targets for AIDS therapy. Science. 1990 Sep 28;249(4976):1533-44. [PubMed:1699273]
  5. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S: 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100. [PubMed:2413459]
  6. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ: Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33. [PubMed:12920168]
External Links
Human Metabolome Database
HMDB0014638
KEGG Drug
D00413
KEGG Compound
C07210
PubChem Compound
35370
PubChem Substance
46508240
ChemSpider
32555
BindingDB
50002692
ChEBI
10110
ChEMBL
CHEMBL129
Therapeutic Targets Database
DAP000701
PharmGKB
PA451954
HET
AZZ
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Zidovudine
ATC Codes
J05AR01 — Zidovudine and lamivudineJ05AR05 — Zidovudine, lamivudine and nevirapineJ05AR04 — Zidovudine, lamivudine and abacavirJ05AF01 — Zidovudine
AHFS Codes
  • 08:18.08.20 — Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
PDB Entries
2jj8 / 3b9l / 3b9m / 3bcr / 4lhm
FDA label
Download (217 KB)
MSDS
Download (57.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
1CompletedNot AvailableInfection, Human Immunodeficiency Virus I1
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
1CompletedTreatmentAIDS-Related Dementia Complex / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentCytopenias / Human Immunodeficiency Virus (HIV) Infections2
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHemophilia A / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV)2
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections44
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infections, Cytomegalovirus1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)6
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pregnancy6
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Toxoplasmosis, Cerebral1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
1Enrolling by InvitationTreatmentAmyotrophic Lateral Sclerosis (ALS)1
1RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV)1
1WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kidney Diseases1
1, 2CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV)1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionHIV Prevention / HIV Transmission / Human Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections2
2CompletedTreatmentAIDS-Related Dementia Complex / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentEncephalopathies / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentEpstein Barr Virus Associated Hodgkin's Lymphoma / Epstein Barr Virus Associated Non Hodgkin's Lymphoma / Post-transplant Lymphoproliferative Disease (PTLD)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections63
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Progressive Multifocal Leukoencephalopathy1
2CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
2CompletedTreatmentInfection, Human Immunodeficiency Virus I2
2CompletedTreatmentMalignant Lymphomas4
2RecruitingTreatmentAdult T-cell lymphomas/leukaemias1
2RecruitingTreatmentCastleman's Disease / Giant Lymph Node Hyperplasia1
2RecruitingTreatmentHHV-8 / Human Immunodeficiency Virus (HIV) / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2RecruitingTreatmentMetastatic Colorectal Cancers1
2SuspendedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
2Unknown StatusPreventionHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusPreventionHuman Immunodeficiency Virus (HIV) / Viral Hepatitis B1
2Unknown StatusTreatmentMalignant Lymphomas2
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2, 3CompletedTreatmentKaposi's Sarcoma AIDS Related1
2, 3CompletedTreatmentPrimary Biliary Cirrhosis (PBC)1
2, 3CompletedTreatmentTropical Spastic Paraparesis1
2, 3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Pediatric AIDS1
2, 3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Zidovudine Adverse Reaction1
3Active Not RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentAcute HIV Infection1
3CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
3CompletedPreventionAcquired Immune Deficiency Syndrome (AIDS)1
3CompletedPreventionDisease Transmission, Vertical / Human Immunodeficiency Virus (HIV) Infections / Vertical Human Immunodeficiency Virus Transmission1
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections6
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections / Plasmodium Infections1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / AIDS-Related Complex1
3CompletedTreatmentAIDS-Related Dementia Complex / Human Immunodeficiency Virus (HIV) Infections2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections45
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii2
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pregnancy3
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
3CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
3CompletedTreatmentInfection, Human Immunodeficiency Virus I1
3TerminatedPreventionDiarrhea1
3TerminatedPreventionHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections2
4Active Not RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections1
4Active Not RecruitingPreventionInfection, Human Immunodeficiency Virus I1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
4CompletedNot AvailableHuman Immunodeficiency Virus (HIV) / Proteinuria1
4CompletedBasic ScienceCardiovascular Disease (CVD) / Dyslipidemias / Glucose Metabolism Disorders / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Metabolic Diseases1
4CompletedDiagnosticCardiovascular Disease (CVD) / HIV-Associated Lipodystrophy Syndrome1
4CompletedOtherHuman Immunodeficiency Virus (HIV)1
4CompletedPreventionCentral Nervous System Diseases / Dementias / Human Immunodeficiency Virus (HIV) Infections1
4CompletedPreventionHuman Immunodeficiency Virus (HIV)1
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections2
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4CompletedTreatmentHemophilia A / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHiv-positive / Malnourished1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)3
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections7
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Human Immunodeficiency Virus I1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Mitochondrial Toxicity1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Tuberculosis1
4CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1)1
4CompletedTreatmentInfection, Human Immunodeficiency Virus I1
4RecruitingPreventionDiabetes Mellitus (DM) / Human Immunodeficiency Virus (HIV) / Insulin Sensitivity1
4RecruitingPreventionHIV/AIDS and Infections1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
4TerminatedTreatmentMalignant Lymphomas / Precancerous/Nonmalignant Condition1
4Unknown StatusPreventionHIV-Associated Lipodystrophy Syndrome / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV)1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) / Kwashiorkor / Marasmus / Severe Acute Malnutrition1
Not AvailableCompletedNot AvailableInfection, Human Immunodeficiency Virus I1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedTreatmentAIDS-Related Dementia Complex / Human Immunodeficiency Virus (HIV) Infections / Neuromuscular Diseases1
Not AvailableCompletedTreatmentChronic Renal Failure (CRF) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedTreatmentCytopenias / Human Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedTreatmentHemophilia A / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections62
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infections, Cytomegalovirus1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Liver Diseases1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphatic Diseases1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)2
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Progressive Multifocal Leukoencephalopathy1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Psoriasis1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
Not AvailableRecruitingNot AvailableAutoimmune Diseases / Neurological Disorders1
Not AvailableRecruitingNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculous Meningitis1

Pharmacoeconomics

Manufacturers
  • Viiv healthcare co
  • Aurobindo pharma ltd inc
  • Cipla ltd
  • Pharmaforce inc
  • Aurobindo pharma ltd
  • Hetero drugs ltd unit iii
  • Matrix laboratories ltd
  • Ranbaxy laboratories ltd
  • Roxane laboratories inc
Packagers
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Aurolife Pharma LLC
  • Camber Pharmaceuticals Inc.
  • Cardinal Health
  • Cipla Ltd.
  • DAVA Pharmaceuticals
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • GlaxoSmithKline Inc.
  • Greenstone LLC
  • H.J. Harkins Co. Inc.
  • Hetero Drugs Ltd.
  • Lake Erie Medical and Surgical Supply
  • Matrix Laboratories Ltd.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Tya Pharmaceuticals
  • ViiV Healthcare ULC
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
Tablet, film coatedOral150 mg/1
Injection, solutionIntravenous10 mg/mL
CapsuleOral100 mg
LiquidIntravenous10 mg
SyrupOral50 mg
TabletOral300 mg
CapsuleOral100 mg/1
SolutionOral50 mg/5mL
SyrupOral10 mg/mL
SyrupOral50 mg/5mL
TabletOral300 mg/1
Tablet, film coatedOral300 mg/1
Prices
Unit descriptionCostUnit
Retrovir 50 mg/5ml Syrup 240ml Bottle74.11USD bottle
Retrovir 300 mg tablet9.1USD tablet
Zidovudine 300 mg tablet6.17USD tablet
Retrovir 100 mg capsule3.09USD capsule
Retrovir iv infusion vial1.61USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2216634No2004-07-202016-03-28Canada
CA2105487No2002-09-242012-03-05Canada
US5905082Yes1996-11-182016-11-18Us
US6294540Yes1998-11-142018-11-14Us
US6417191Yes1996-09-282016-09-28Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)113-115 °CPhysProp
water solubility2.01E+004 mg/L (at 25 °C)PHYSICIANS DESK REFERENCE (2003)
logP0.05HANSCH,C ET AL. (1995)
Caco2 permeability-5.16ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility16.3 mg/mLALOGPS
logP-0.1ALOGPS
logP-0.3ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)9.96ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area108.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity61.7 m3·mol-1ChemAxon
Polarizability24.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9343
Blood Brain Barrier+0.6224
Caco-2 permeable-0.8728
P-glycoprotein substrateNon-substrate0.6959
P-glycoprotein inhibitor INon-inhibitor0.9118
P-glycoprotein inhibitor IINon-inhibitor0.8981
Renal organic cation transporterNon-inhibitor0.8798
CYP450 2C9 substrateNon-substrate0.663
CYP450 2D6 substrateNon-substrate0.8987
CYP450 3A4 substrateSubstrate0.5329
CYP450 1A2 substrateNon-inhibitor0.9355
CYP450 2C9 inhibitorNon-inhibitor0.9143
CYP450 2D6 inhibitorNon-inhibitor0.9315
CYP450 2C19 inhibitorNon-inhibitor0.9175
CYP450 3A4 inhibitorNon-inhibitor0.848
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9585
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7484
BiodegradationReady biodegradable0.5673
Rat acute toxicity2.0464 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7124
hERG inhibition (predictor II)Non-inhibitor0.8821
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0190000000-46ee7eb3034a9b20706d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0790000000-19916045eff2f2277d60
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0fk9-0900000000-836aff54cb90ce573db4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-cb1ef888d872056bce56
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-0900000000-97660ea43493fa2fa991
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-05fr-0900000000-407e81a32dbf5eb07134
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0900000000-743290b40f399a527da5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0900000000-667b9ae1f4c499b8cef6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0900000000-c6bf89700e58ad9aff83
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-1900000000-b644d0eec4449bae7675
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-01t9-2900000000-d794028d708aa5c5d04f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03gi-5900000000-b2b0a6ddec7e2e91e8c4
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrimidine 2',3'-dideoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at positions 2 and 3.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Pyrimidine nucleosides
Sub Class
Pyrimidine 2',3'-dideoxyribonucleosides
Direct Parent
Pyrimidine 2',3'-dideoxyribonucleosides
Alternative Parents
Pyrimidones / Hydroxypyrimidines / Hydropyrimidines / Tetrahydrofurans / Heteroaromatic compounds / Azo imides / Azo compounds / Oxacyclic compounds / Azacyclic compounds / Primary alcohols
show 4 more
Substituents
Pyrimidine 2',3'-dideoxyribonucleoside / Pyrimidone / Hydroxypyrimidine / Hydropyrimidine / Pyrimidine / Tetrahydrofuran / Heteroaromatic compound / Azo imide / Azo compound / Oxacycle
show 13 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
azide, pyrimidine 2',3'-dideoxyribonucleoside (CHEBI:10110)

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna-dna hybrid ribonuclease activity
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q72547
Uniprot Name
Reverse transcriptase/RNaseH
Molecular Weight
65223.615 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Barry M, Gibbons S, Back D, Mulcahy F: Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209. [PubMed:9084959]
  3. De Clercq E: Antiretroviral drugs. Curr Opin Pharmacol. 2010 Oct;10(5):507-15. doi: 10.1016/j.coph.2010.04.011. Epub 2010 May 12. [PubMed:20471318]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Trna binding
Specific Function
Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal som...
Gene Name
TERT
Uniprot ID
O14746
Uniprot Name
Telomerase reverse transcriptase
Molecular Weight
126995.435 Da
References
  1. Leeansyah E, Cameron PU, Solomon A, Tennakoon S, Velayudham P, Gouillou M, Spelman T, Hearps A, Fairley C, Smit de V, Pierce AB, Armishaw J, Crowe SM, Cooper DA, Koelsch KK, Liu JP, Chuah J, Lewin SR: Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. doi: 10.1093/infdis/jit006. Epub 2013 Jan 9. [PubMed:23303810]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]
  3. Authors unspecified: Letter: Exercise testing and coronary heart disease. N Engl J Med. 1975 Dec 4;293(23):1208-10. [PubMed:1186798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
TK1
Uniprot ID
P04183
Uniprot Name
Thymidine kinase, cytosolic
Molecular Weight
25468.455 Da
References
  1. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, Lehrman SN, Bolognesi DP, Broder S, Mitsuya H, et al.: Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7. [PubMed:2430286]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, Greenblatt DJ: Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33. [PubMed:12920168]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
Inducer
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. doi: 10.1124/dmd.104.000794. Epub 2004 Aug 10. [PubMed:15304429]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Quevedo MA, Moroni GN, Brinon MC: Human serum albumin binding of novel antiretroviral nucleoside derivatives of AZT. Biochem Biophys Res Commun. 2001 Nov 9;288(4):954-60. [PubMed:11689002]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Worner P, Brossmer R: Platelet aggregation and the release induced by inophores for divalent cations. Thromb Res. 1975 Apr;6(4):295-305. [PubMed:1094583]
  2. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]
  3. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [PubMed:19953504]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]
  2. VanWert AL, Gionfriddo MR, Sweet DH: Organic anion transporters: discovery, pharmacology, regulation and roles in pathophysiology. Biopharm Drug Dispos. 2010 Jan;31(1):1-71. doi: 10.1002/bdd.693. [PubMed:19953504]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Endou H: Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. [PubMed:11861798]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Pyrimidine- and adenine-specific:sodium symporter activity
Specific Function
Sodium-dependent and pyrimidine-selective. Exhibits the transport characteristics of the nucleoside transport system cit or N2 subtype (N2/cit) (selective for pyrimidine nucleosides and adenosine)....
Gene Name
SLC28A1
Uniprot ID
O00337
Uniprot Name
Sodium/nucleoside cotransporter 1
Molecular Weight
71583.18 Da
References
  1. Cano-Soldado P, Lorrayoz IM, Molina-Arcas M, Casado FJ, Martinez-Picado J, Lostao MP, Pastor-Anglada M: Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1). Antivir Ther. 2004 Dec;9(6):993-1002. [PubMed:15651758]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Nucleoside transmembrane transporter activity
Specific Function
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, ...
Gene Name
SLC29A2
Uniprot ID
Q14542
Uniprot Name
Equilibrative nucleoside transporter 2
Molecular Weight
50112.335 Da
References
  1. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD: Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol. 2001 Apr-Jun;18(2):161-7. [PubMed:11463208]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):441-9. [PubMed:16791115]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Abla N, Chinn LW, Nakamura T, Liu L, Huang CC, Johns SJ, Kawamoto M, Stryke D, Taylor TR, Ferrin TE, Giacomini KM, Kroetz DL: The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther. 2008 Jun;325(3):859-68. doi: 10.1124/jpet.108.136523. Epub 2008 Mar 25. [PubMed:18364470]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Acts as a multispecific organic anion pump which can transport nucleotide analogs.
Gene Name
ABCC5
Uniprot ID
O15440
Uniprot Name
Multidrug resistance-associated protein 5
Molecular Weight
160658.8 Da
References
  1. Jorajuria S, Dereuddre-Bosquet N, Becher F, Martin S, Porcheray F, Garrigues A, Mabondzo A, Benech H, Grassi J, Orlowski S, Dormont D, Clayette P: ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28. [PubMed:15456083]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Pan G, Giri N, Elmquist WF: Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos. 2007 Jul;35(7):1165-73. Epub 2007 Apr 16. [PubMed:17437964]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:41